Le Lézard
Classified in: Health
Subject: SVY

Sepsis Diagnostics Market Worth $890 million | MarketsandMarketstm.


CHICAGO, April 8, 2024 /PRNewswire/ -- Sepsis Diagnostics Market in terms of revenue was estimated to be worth $634 million in 2024 and is poised to reach $890 million by 2029, growing at a CAGR of 7.0% from 2024 to 2029 according to a new report by MarketsandMarketstm.

MarketsandMarkets

Factors such the commercialization and availability of a wide variety of approved sepsis diagnostic devices, rising prevalence of sepsis, incidence of hospital-acquired infections, growing number of surgical procedures and increasing geriatric population are high growth prospects for the sepsis diagnostics market during the forecast period.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=92673155

Browse in-depth TOC on "Sepsis Diagnostics Market"

167 - Tables

18 - Figures

266 - Pages

Sepsis Diagnostics Market Scope:

Report Coverage

Details

Market Revenue in 2024

$634 million

Estimated Value by 2029

$890 million

Growth Rate

Poised to grow at a CAGR of 7.0%

Market Size Available for

2021?2029

Forecast Period

2024?2029

Forecast Units

Value (USD Million)

Report Coverage

Revenue Forecast, Competitive Landscape, Growth Factors, and Trends

Segments Covered

Technology, Product, Method, Pathogen Type, Test Type, End user, and Region

Geographies Covered

North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa

Report Highlights

Updated financial information / product portfolio of players

Key Market Opportunities

Rapid diagnostic/POC techniques development for early sepsis diagnosis

Key Market Drivers

Increasing hospital-acquired infection incidences

The molecular diagnostics segment is to register a significant growth rate over the forecast period of 2024-2029.

Based on the technology, over the forecast period of 2024-2029, the molecular diagnostics segment is to register a significant growth rate. The sepsis diagnostics product market is segmented into blood culture, immunoassays, molecular diagnostics, flow cytometry, microfluidics, and biomarkers. The molecular diagnostics segment comprises PCR, microarray, peptide nucleic acid fluorescent in situ hybridization and DNA sequencing. The key factors encouraging the growth of mesh segment during the forecast period are the the growing need for early disease diagnosis and various advantages offered by this technique as compared others.

The hospitals & speciality clinics segment accounted for the largest share of sepsis diagnostics market in 2024-2029.

Based on end user, the hospitals & speciality clinics segment is estimated to hold the largest market share of the sepsis diagnostics market during the forecast period. Increasing number of patients hospitalized with sepsis, in-house hospital laboratories perform a large number of blood culture tests to identify the blood stream infections (BSIs caused by bacteria, fungi/yeast, or viruses) and high prevalence of sepsis coupled with a large number of fatalities caused by the illness lead to a large share of the segment.

Asia Pacific registered the highest CAGR in the market during the forecast period.

In 2024, Asia Pacific is expected to register the highest CAGR in the market for sepsis diagnostics during the forecast period. Asia Pacific comprises China, India, South Korea, Taiwan, and Singapore, and the rest of Asia Pacific. Factors such as the growing adoption of advanced treatment options, presence of a large target patient population and improving diagnosis and treatment rates are driving the growth of the APAC sepsis diagnostics market during the forecast period.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=92673155

Sepsis Diagnostics Market Dynamics:

Drivers: 

  1. Increasing hospital-acquired infection incidences

Restraints:

  1. High costs of automated diagnostic devices

Opportunities:

  1. Rapid diagnostic/POC techniques development for early sepsis diagnosis

Challenge:

  1. Dearth of skilled healthcare professionals

Key Market Players of Sepsis Diagnostics Industry:

As of 2023, prominent players in sepsis diagnostics are bioMérieux (France), Becton Dickinson Company (US), Danaher Corporation (US), Abbott Laboratories (US), and Roche Diagnostics (Switzerland). Other players include T2 Biosystems (US), Thermo Fisher Scientific (US), Bruker (US), EKF Diagnostics (UK), Immunexpress (Australia), among others.

A breakdown of the primary participants referred to for this report is provided below:

Recent Developments of Sepsis Diagnostics Industry:

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=92673155

Sepsis Diagnostics Market - Key Benefits of Buying the Report:

The report will enable established firms as well as entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them to garner a larger market share. Firms purchasing the report could use one or a combination of the below-mentioned strategies to strengthen their market presence.

This report provides insights on the following pointers:

Related Reports:

Transplant Diagnostics Market - Global Forecasts to 2028

Molecular Diagnostics Market - Global Forecasts to 2028

Blood Culture Tests Market- Global Forecasts to 2028

Point of Care Molecular Diagnostics Market - Global Forecasts to 2028

Point of Care Diagnostics Market - Global Forecasts to 2028

About MarketsandMarketstm:

MarketsandMarketstm has been recognized as one of America's best management consulting firms by Forbes, as per their recent report.

MarketsandMarketstm is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

Earlier this year, we made a formal transformation into one of America's best management consulting firms as per a survey conducted by Forbes.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStoretm (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

To find out more, visit www.MarketsandMarketstm.com or follow us on Twitter, LinkedIn and Facebook.

Contact:
Mr. Aashish Mehra
MarketsandMarketstm INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: [email protected]

Research Insights: https://www.marketsandmarkets.com/ResearchInsight/sepsis-diagnostic-market.asp

Visit Our Website: https://www.marketsandmarkets.com/

Content Source: https://www.marketsandmarkets.com/PressReleases/sepsis-diagnostic.asp

Logo - https://mma.prnewswire.com/media/2297424/MarketsandMarkets_Logo.jpg


These press releases may also interest you

10 mai 2024
On May 10, 2024, the impactful international academic journal, Science Immunology, a sub-journal of Science, published a research paper titled "Single-cell analysis of anti-BCMA CAR T cell therapy in patients with central nervous system...

10 mai 2024
Fitness International, LLC opened a new Club Studio location in Kingwood, Texas. The new 40,000 square foot club features five innovative boutique fitness studios that were carefully curated to create a unique experience, along with recovery services...

10 mai 2024
Mirum Pharmaceuticals, Inc. today announced that on May 10, 2024, the Compensation Committee of Mirum's Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 38,600 shares of common stock and 19,300...

10 mai 2024
Evolus, Inc. , a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant of non-qualified stock options to purchase an aggregate of 10,990 shares of Evolus and an aggregate of 42,759...

10 mai 2024
Inhibrx, Inc. ("Inhibrx," or the "Company") today announced that in connection with the previously announced distribution by the Company of 92% of shares of common stock of its subsidiary Inhibrx Biosciences, Inc. ("SpinCo") to holders of shares of...

10 mai 2024
Asia Green Biotechnology Corp. ("Asia Green" or the "Company") announces that, further to its news releases dated April 17, 2024, April 26, 2024, and May 8, 2024, the Management Cease Trade Order ("MCTO") issued by the...



News published on and distributed by: